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SUMMARY
Overactive p53 has been proposed as an important pathophysiological factor for bone marrow failure syndromes, including Fanconi
anemia (FA). Here, we report a p53-dependent effect on hematopoietic stem and progenitor cell (HSPC) proliferation in mice deficient
for the FA gene Fanca. Deletion of p53 in Fanca/ mice leads to replicative exhaustion of the hematopoietic stem cell (HSC) in transplant
recipients. Using Fanca/ HSCs expressing the separation-of-function mutant p53515C transgene, which selectively impairs the p53 function in apoptosis but keeps its cell-cycle checkpoint activities intact, we show that the p53 cell-cycle function is specifically required for
the regulation of Fanca/ HSC proliferation. Our results demonstrate that p53 plays a compensatory role in preventing FA HSCs from
replicative exhaustion and suggest a cautious approach to manipulating p53 signaling as a therapeutic utility in FA.

INTRODUCTION
The tumor suppressor p53 is a key component of the
DNA damage-response network that activates vital
damage-control procedures to restrict aberrant cell growth
in response to DNA damage, oncogene activation, and
loss of normal cell contacts, by maintaining the balance
between cell survival and apoptosis (Levine and Oren,
2009; Murray-Zmijewski et al., 2008). Although p53 mutations are common in solid tumors, such mutations are
found at a lower frequency in hematologic malignancies
(Krug et al., 2002; Prokocimer and Rotter, 1994). In
addition, these mutations may abolish some, but not
necessarily all, of the functions of the p53 protein (Abbas
et al., 2011; Krug et al., 2002; Pant et al., 2012; Prokocimer
and Rotter, 1994). Recently, several studies using mouse
models suggest a critical role for p53 in hematopoietic
stem cell (HSC) self-renewal and quiescence (Liu et al.,
2009; TeKippe et al., 2003). Therefore, precise regulation
of p53 activity is likely to be important in determining
the response of HSCs to cellular stresses. Insufficient
p53 activation would favor cell survival, but puts cells at
risk for loss of genomic integrity. In contrast, excessive
p53 activation could compromise steady-state hematopoiesis and its recovery following exogenous marrow insult by
causing too many cells to be eliminated (Wang et al., 2011).
In the context of Fanconi anemia (FA), a genetic disorder
characterized by a variety of symptoms including skeletal
and developmental defects, bone marrow failure (BMF),
and a high predisposition to cancer (Bagby, 2003;
Kottemann and Smogorzewska, 2013; Mamrak et al.,
2017), emerging evidence suggests that p53 deficiency

may increase cancer development in patients with FA and
FA mice (Ceccaldi et al., 2011; Houghtaling et al., 2005).
Conversely, recent studies show that overactive p53 could
cause hematopoietic stem and progenitor cell (HSPC)
depletion in the bone marrow (BM) of FA patients (Ceccaldi
et al., 2012). These studies corroborate a critical role of the
FA proteins in cooperating with p53 in apoptosis and
cell-cycle regulation after DNA damage induced by the
physiologic stress response.
In the present study, we demonstrate a p53-dependent
HSPC proliferation regulation in mice deficient for the
Fanca gene in the FA pathway. Using Fanca/ HSCs deleted
for the entire p53 gene or expressing the p53515C transgene,
which selectively impairs the p53 function in apoptosis
while keeping its cell-cycle checkpoint activities intact, we
show that the p53 cell-cycle function is specifically required
for the regulation of FA HSC proliferation. Our findings
suggest that overactive p53 may represent a compensatory
checkpoint mechanism for FA HSC proliferation.

RESULTS
Loss of p53 in Fanca/ Mice Leads to Increased HSPC
Pool but Progressive Decline of HSC Reservoir
Recent studies showed that p53 is upregulated in HSPCs of
FA patients, and postulated that overactive p53 response
to DNA damage might be responsible for HSC depletion
in FA (Ceccaldi et al., 2012). To study the in vivo effect of
p53 on the maintenance of FA HSCs, we deleted the p53
gene in a murine model of FA (Fanca/) mice (Wong
et al., 2003). The levels of both total and phosphorylated
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Figure 1. Loss of p53 in Fanca/ Mice Leads to Increased HSPC Pool but Progressive Decline of HSC Reservoir
(A) Elevated p53 protein level in Fanca/ HSPCs. BM LSK (LinSCA-1+C-KIT+) cells were isolated from mice with the indicated genotype,
and cell lysates were subjected to immunoblot analysis using antibodies specific for total p53, phosphor-p53 (P-p53), or b-actin.
The relative levels of total p53 or of P-p53 to b-actin are indicated below the blot. Each lane contains proteins from 30,000 LSK cells.
(B) Immunostaining of p53 protein in phenotypic HSCs. Freshly isolated CD34 LSK cells from mice with the indicated genotype were
immunostained to detect p53 (green). Nuclei were visualized using DAPI (blue). Scale bars, 10 mm.
(C) Progressive decrease of HSPCs in p53-deficient Fanca/ mice. Whole bone marrow cells (WBMCs) isolated from mice with the indicated
genotype were subjected to flow cytometric analysis for LSK staining. Representative plots for 8 weeks (left) and quantification for
both 8 and 20 weeks (right) are shown. Results are means ± SD of three independent experiments (n = 9 per group).
(D) Progressive decrease of HSCs in p53-deficient Fanca/ mice. WBMCs isolated from mice with the indicated genotype were subjected to
flow cytometric analysis for SLAM (LSK CD150+CD48) staining. Representative plots for 20 weeks (left) and quantification for both 8 and
20 weeks (right) are shown. Results are means ± SD of three independent experiments (n = 9 per group).
*p < 0.05; **p < 0.01; ***p < 0.001.
p53 proteins were higher in LinSCA-1+C-KIT+ (LSK) cells,
a population containing HSCs and multipotential progenitors, of Fanca/ mice than those of wild-type (WT) mice
340 Stem Cell Reports j Vol. 10 j 339–346 j February 13, 2018

(Figure 1A). To examine the p53 protein in phenotypic
HSCs, we isolated BM CD34 LSK cells, by fluorescenceactivated cell sorting for immunostaining with an

anti-p53 antibody. Consistent with the western blot
results, the level of immunostained p53 was higher in
Fanca/ HSCs compared with WT cells (Figure 1B). We
also used the HSCs from p53/ and double-knockout
(dKO) (p53/Fanca/) mice to verify the specificity of
the p53 antibody.
Consistent with previous reports (Liu et al., 2009), loss of
p53 increased both the frequencies of LSK cells (2- to
3-fold) and phenotypic (LSK CD150+ CD48; SLAM;
Kiel et al., 2005) HSCs (2-fold) compared with WT mice
(Figures 1C and 1D). Interestingly, we found that the
expansion of p53/ SLAM cells in young mice (8 weeks
of age) was followed by a significant decline in SLAM
frequency at 20 weeks of age (Figure 1D), suggesting a
possible replicative exhaustion. Importantly, the dKO
(Fanca/p53/) HSCs showed much more dramatic
exhaustion than those deficient for p53 alone at 20 weeks
of age. Specifically, at 8 weeks of age, dKO mice showed a
significant increase in LSK and SLAM cells. However, at
20 weeks of age, the frequencies of both LSK and SLAM cells
in dKO mice declined significantly, compared with those
at 8 weeks of age, which was equivalent to or lesser than
that of WT or single-knockout (sKO) Fanca/ mice (Figures
1C and 1D). Furthermore, SLAM cells deficient for Fanca
alone did not undergo exhaustion (Figure 1D). These
results suggest that the Fanca deficiency may collaborate
with p53 loss in HSC replicative exhaustion.
p53 Deficiency Leads to Proliferative Exhaustion of
Fanca/ HSCs
The observation that loss of p53 decreased HSC frequency
in Fanca/ mice prompted us to measure HSC proliferation in dKO mice by bromodeoxyuridine (BrdU) incorporation in vivo. After BrdU administration, we harvested BM
cells from the mice and measured the percentage of LSK
CD34 HSCs that had incorporated BrdU. Loss of p53
increased the percentage of HSCs incorporating BrdU in
both WT and Fanca/ mice, with approximately 40%
(among total 16.8% LSK CD34 cells) of the p53/ HSCs
and 30% (among total 13.7% LSK CD34 cells) of the
dKO HSCs incorporating BrdU in vivo at 20 weeks of age
(Figure 2A). Similar results were obtained with progenitor
proliferation assay, in which p53 deficiency led to more
than 2-fold increase in colony formation in both WT and
Fanca/ mice compared with their respective controls at
8 and 20 weeks of age (Figure 2B).
To study the effect of p53 deficiency on Fanca/ HSC
proliferation under replicative stress, we performed
competitive repopulating experiments by transplanting
50 SLAM cells from WT, sKO, or dKO into lethally
irradiated syngeneic recipient mice (CD45.1) along with
4 3 105 protector BM cells (CD45.1). We found that the
repopulating abilities of both the p53/ and dKO cells

were higher than either WT or Fanca/ cells at 8 and
12 weeks post-transplantation (Figure 2C). However, the
repopulating capacity of the dKO HSCs underwent progressive decline thereafter, as demonstrated by a gradual
decrease in donor-derived nucleated cells in the peripheral
blood of the recipient mice (Figure 2C). The donor p53/
HSCs also experienced a decline in repopulating potential,
albeit less dramatic than the dKO HSCs (Figure 2C).
The results described above suggest that the dKO HSCs
might have undergone replicative exhaustion in transplant
recipients. To test this notion, we performed competitive
repopulating unit (CRU) assays with limiting dilutions of
SLAM cells from these four genotypes of mice. Various
doses of sorted SLAM cells (15, 45, and 150 cells) were
mixed with protector BM cells and transplanted into
lethally irradiated Boy J mice. Peripheral blood samples
were collected at 8 and 16 weeks post-transplantation
and analyzed for donor engraftment. Poisson statistical
analysis at 8 weeks post-transplant showed >5-fold reduction in CRUs in dKO mice than in WT mice (CRUs: 1 in
20.2 in WT mice; 1 in 24.7 in p53/ mice; 1 in 26.8 in
Fanca/ mice; and 1 in 139.2 in dKO mice). This reduction
in CRUs in dKO mice increased to >30-fold when estimated
at 16 weeks post-transplantation (CRUs: 1 in 15.9 in WT
mice; 1 in 68.6 in p53/ mice; 1 in 83.5 in Fanca/
mice; and 1 in 492 in dKO mice) (Figure 2D). These results
indicate more severely impaired HSC functionality caused
by simultaneous deficiency of FA and p53. Taken together,
these results suggest that although deletion of p53 in
Fanca/ mice expanded the HSPC pool, these two genetic
alterations cooperate somehow to induce progressive HSC
exhaustion.
The Cell-Cycle Regulatory Activity of p53 Is Required
for Preventing Fanca/ HSC Exhaustion
The increase in HSC turnover in dKO mice measured by
BrdU incorporation in vivo (Figure 2A) would suggest
decreased quiescence, which might be the cause of
reduced repopulating potential we observed with the
dKO HSCs (Figures 2C and 2D). Cell-cycle analyses using
an antibody to Ki-67, a nuclear marker of cell cycling,
showed that 30%–40% fewer HSCs were quiescent
(in the G0 phase) in p53/ and dKO mice compared
with WT and Fanca/ mice at 20 weeks of age (Figure 3A).
Quiescence was also decreased in p53/ and dKO mice
at 8 weeks of age, albeit less profound than that observed
in older (20 weeks) mice (Figure 3A).
It is well known that p53 controls the G1/S cell-cycle
checkpoint and is required for both apoptosis and senescence in various cellular contexts (Iwakuma and Lozano,
2007). Given that loss of p53 alone reduced quiescence
without causing significant HSC exhaustion, we postulated
that the FA proteins cooperate with the cell-cycle activity of
Stem Cell Reports j Vol. 10 j 339–346 j February 13, 2018 341

Figure 2. p53 Deficiency Leads to Proliferative Exhaustion of Fanca/ HSCs
(A) p53 deficiency decreases Fanca/ HSC quiescence. BM cells from mice with the indicated genotype at 8 and 20 weeks of age
were gated for CD34 LSK population and analyzed for BrdU incorporation. Representative plots for 20 weeks (left) and quantification for
both 8 and 20 weeks (right) are shown. Results are means ± SD of two independent experiments (n = 6 per group).
(B) Loss of p53 promotes Fanca/ HSPC proliferation. LSK cells isolated from mice with the indicated genotype at 8 and 20 weeks of age
were plated in cytokine-supplemented methylcellulose medium. Colonies were enumerated on day 7 after plating. Results are means ± SD
of three independent experiments (n = 9 per group).
(C) Loss of p53 causes progressive decline in repopulating potential of Fanca/ HSCs. 50 SLAM cells from mice with the indicated
genotype (CD45.2) at 20 weeks of age, along with 4 3 105 protector BM cells (CD45.1), were transplanted into lethally irradiated
Boy J recipients. Donor-derived chimera was detected by flow cytometry at the indicated weeks post-transplant.
(D) Competitive repopulating units (CRUs) determined by limiting dilution BM transplantation assay. Graded numbers of test SLAM cells
(CD45.2+) from mice with the indicated genotype at 20 weeks of age were mixed with 4 3 105 protector BM cells (CD45.1) and transplanted
into irradiated congenic recipients (CD45.1+). Plotted are the percentages of recipient mice containing less than 1% CD45.2+ blood
nucleated cells at 16 weeks after transplantation. The frequency of functional HSCs was calculated according to Poisson statistics.
*p < 0.05; **p < 0.01.
p53 in HSC maintenance. To test this hypothesis, we
crossed our Fanca/ mice to a mutant p53 mouse strain
harboring a separation-of-function mutation in p53,
p53515C, in which its apoptotic function is abolished
but its cell-cycle checkpoint activities remain intact
(Liu et al., 2004). We confirmed the functionality of
the p53515C mutation using three independent assays:
cell-cycle analysis, gene expression profiling of p53 targets,
and apoptosis analysis. First, cell-cycle analyses using an
antibody to Ki-67 showed that cell-cycle patterns of BM
SLAM cells in p53515C/515C were not significantly different
from those in WT or Fanca/ littermates (Figure 3B).
Importantly, p53515C/515C had minimal effect on the
quiescence of Fanca/ HSCs. Second, RT-PCR analysis of
342 Stem Cell Reports j Vol. 10 j 339–346 j February 13, 2018

expression levels of p53 target genes in cell-cycle control
(Ccng1, p21) and apoptosis (Puma, Noxa) in BM SLAM
cells showed that the transcription of the cell-cycle genes
was similar among WT, p53515C/515C, and p53515C/515C
Fanca/ mice; however, we observed a dramatic difference
between p53/ Fanca/ and p53515C/515C Fanca/ mice,
in which the expression of the cell-cycle genes was
abolished in p53/ Fanca/ mice, but remained robust
in p53515C/515C Fanca/ mice (Figure 3C). We found that
the expression of the apoptosis genes was abolished in
the p53515C/515C background (Figure 3C). We also noticed
that the mRNA levels of cell-cycle and apoptosis genes
were elevated in Fanca/ BM SLAM cells compared with
WT SLAM cells (Figure 3C). Lastly, we evaluated cell

Figure 3. The Cell-Cycle Regulatory Activity of p53 Is Required for Preventing Fanca/ HSC Exhaustion
(A) Cell-cycle analysis of SLAM cells. BM cells from mice with the indicated genotype at 8 and 20 weeks of age were gated for the SLAM
population, and analyzed for cell-cycle phases by flow cytometry. Representative dot plots for 20 weeks (left) and quantification of
quiescent (G0) cells within the SLAM population for both 8 and 20 weeks (right) are shown. Results are means ± SD of three independent
experiments (n = 9 per group).
(B) Quiescence is not compromised in Fanca/ SLAM cells expressing the p53515C/515C mutation. BM cells from mice with the indicated
genotype at 20 weeks of age were gated for the SLAM population, and analyzed for cell-cycle phases by flow cytometry. Quantification of
quiescent (G0) cells within the SLAM population is shown. Results are means ± SD of three independent experiments (n = 9 per group).
(C) qRT-PCR analysis of the expression of apoptosis and cell-cycle genes. SLAM cells isolated from mice with the indicated genotype at
20 weeks of age were subjected to qPCR analysis using primers for the indicated genes. Levels of the expression in each sample were
normalized to the level of GAPDH mRNA, and the expression levels of the WT samples were normalized as 100.
(D) The p53515C mutation selectively impairs the p53 function in apoptosis. Cells from mice with the indicated genotype at 20 weeks of age
were gated for SLAM population and analyzed for apoptosis by Annexin V and 7AAD. Quantification is shown. Results are means ± SD of
three independent experiments (n = 9 per group).
(E) qRT-PCR analysis of the expression of negative cell-cycle regulator genes. SLAM cells isolated from mice with the indicated genotype at
20 weeks of age were subjected to qPCR analysis using primers for the indicated genes. Levels of the expression in each sample were
normalized to the level of GAPDH mRNA, and the expression levels of the WT samples were normalized as 100.
Statistical significance compared with WT. *p < 0.05; **p < 0.01; ***p < 0.001.
apoptosis by Annexin V staining and found that p53515C
significantly reduced the frequency of apoptotic (Annexin
V+/PI–) HSCs, similar to the null mice (Figure 3D). Collectively these data demonstrate that the p53515C mutation
selectively impairs the p53 function in apoptosis, but
leaves cell-cycle checkpoint unaffected.
The observation that Fancc/ HSCs carrying the p53515C
mutation lost apoptosis but remained quiescent prompted
us to investigate the underlying molecular mechanism. To
this end, we analyzed the p53-related negative cell-cycle
regulators p15INKb, p16INK4a, p19ARF, and p21Cip1/WAF1
(Bartek and Lukas, 2001). Interestingly, three of the four
G1 arrest-associated cell-cycle regulators, namely p16INK4a,
p19Arf, and p21Cip1/WAF1, exhibited significantly higher
expression in the SLAM cells isolated from the Fancc/ littermates in the p53515C background (p53515C/515C Fanca/)
than those in the p53-null background (p53/ Fanca/;

Figure 3E). These results suggest that a pathway regulating
the expression of p16INK4a, p19Arf, and p21Cip1/WAF1 may act
as molecular checkpoints for cycling and thus expansion of
FA HSCs.
Next, we performed limiting dilution CRU assays to
determine whether an intact cell-cycle function of p53
could prevent FA HSC exhaustion in vivo, by transplanting
grading numbers of donor CD45.2+ bone marrow SLAM
cells, along with protector BM cells, into lethally irradiated
CD45.1+ congenic mice. At 16 weeks after transplant, the
frequency of CRUs in phenotypic BM SLAM cells of
p53515C/515C Fanca/ mice was 1 in 97, significantly higher
than the frequency, 1 in 458, in those of p53/ Fanca/
mice (Table 1). It should be noted that the frequency of
CRUs in SLAM cells from p53/ (1 in 63) or Fanca/
(1 in 79) sKO mice, but not from those of p53515C/515C
(1 in 21) mice, was significantly lower than the frequency
Stem Cell Reports j Vol. 10 j 339–346 j February 13, 2018 343

Table 1. Competitive Repopulating Units
/

Genotype WT

p53
Fanca/ 20

CRU
1/19 1/79
frequency

1/63

/

/

Fanca
p53515C p53/

Fanca
p53515C

1/21

1/97

1/458

of WT cells (1 in 19) (Table 1). These results indicate that the
p53-dependent cell-cycle control is specifically required for
avoiding further deterioration of FA HSC function. These
data also suggest that total elimination of p53 function
may promote FA HSC exhaustion.

DISCUSSION
In this study, we used several mouse models of FA and p53
to study the in vivo effect of overactive p53 on FA hematopoiesis. Our results suggest that overactive p53 may play a
compensatory role in preventing murine FA HSCs from
replicative exhaustion. In this context, our study thus
cautions that targeting p53 in FA, while potentially
eliciting temporary growth improvement, might have the
unanticipated detrimental consequence of increasing the
long-term risk of HSC defect leading to BMF, which is the
hematopoietic hallmark of FA.
One interesting observation of our study is that p53 deficiency in Fanca/ mice increases the HSC pool in young
mice (Figure 1). These results are consistent with previous
reports that HSCs expressing lower levels of p53 protein
can outcompete WT HSCs independent of DNA damage
(Bondar and Medzhitov, 2010; Marusyk et al., 2010).
Although the underlying mechanism remains unclear,
we show that, in murine HSCs, some of the p53-related
negative cell-cycle regulators, such as p16INK4a, p19ARF,
and p21Cip1/WAF1, may be responsible for limiting the
expansion of HSCs with normal (WT) or higher (FA) levels
of p53. In addition, other mechanisms may also be in play
in the context of defects in FA HSCs. For instance, there is
evidence that FA HSPCs show abnormalities in reactive
oxygen species detoxification (Du et al., 2008) and
cytokine signaling (Anur et al., 2012; Li et al., 2007).
Another related mechanism is the aberrant activation of
the TLR4/8 and MAP kinase pathways that release myelosuppressive cytokines, such as tumor necrosis factor alpha,
to which FA HSCs are hypersensitive (Svahn et al., 2015;
Vanderwerf et al., 2009). It is also reported that mice deficient for FA DNA repair pathway (Fancd2) and acetaldehyde detoxification (aldehyde dehydrogenase 2; Aldh2)
suffer dramatic reduction in the HSC pool (Garaycoechea
et al., 2012). More recently, it has been shown that FA
deficiency exacerbates the transforming growth factor
b signaling pathway, which is detrimental to FA HSCs
(Zhang et al., 2016).
344 Stem Cell Reports j Vol. 10 j 339–346 j February 13, 2018

HSC exhaustion, defined as a decrease in the number of
HSCs caused by their enhanced cell cycling, is considered
one cellular mechanism of BMF in FA. Under steady state,
FA mice, including Fanca/, Fancb/, Fancc/, Fancd2/

, and Fancg/ mice, fail to recapitulate the anemia phenotype of FA patients (Carreau et al., 1998; Cheng et al., 2000;
Du et al., 2015; Yang et al., 2001; Zhang et al., 2010). Our
current study suggests that overactive p53 may be a causal
factor that prevents or delays the loss of HSCs in Fanca/
mice. Several studies, including ours, have shown that
the p53 pathway is upregulated in several FA mouse models
(Du et al., 2016; Ceccaldi et al., 2012; Freie et al., 2004). In
two well-established assays designed to evaluate selfrenewal (competitive limiting dilution assay) and hematopoietic repopulating (competitive BM transplantation
assay) ability of an HSC, we observed a significant decrease
in both CRU and long-term repopulation by Fanca/
p53/ dKO HSCs compared with Fanca/ cells (Figure 2).
Thus, it is tempting to speculate that a p53 function is
required for the maintenance Fanca/ HSCs. Furthermore,
we demonstrated that replicative exhaustion, as demonstrated by an initial expansion followed by a progressive
decline of both phenotypic HSCs and their long-term
repopulating activity, requires simultaneous inactivation
of Fanca and p53. This suggests that the HSC exhaustion
phenotype observed in Fanca/ p53/ dKO mice may
result from a synergistic effect of the double deficiencies.
In this context, we speculate a coordinate regulation of
HSC functions by the p53 and FA pathways.
The roles of p53 in both apoptosis and cell-cycle arrest are
well understood. However, recent studies suggest that the
most dramatic cellular outcomes mediated by p53 function
can occur independently of, or separately from, these roles
(Iwakuma and Lozano, 2007; Liu et al., 2004). In the current study, we have utilized FA HSCs deleted for the entire
p53 gene or expressing the p53515C transgene, which selectively impair the p53 function in apoptosis, to demonstrate
that the p53 cell-cycle function is specifically required for
the regulation of FA HSC proliferation. This finding suggests enticing hypotheses to explain the compensatory
role of overactive p53 in preventing FA HSCs from replicative exhaustion and leukemic transformation. Future
studies will elucidate the interplay between the cell-cycle
function of p53 and FA HSC maintenance.

EXPERIMENTAL PROCEDURES
Detailed methods are included in the Supplemental Information.

Mice and Treatment
Fanca+/ and p53R172P/R172P mice (C57BL/6, CD45.2+) were
provided by Dr. Madeleine Carreau (Laval University) and
Dr. Guillermina Lozano (University of Texas MD Anderson Cancer

Center), respectively (Liu et al., 2004; Wong et al., 2003). p53/
Fanca/ mice were generated by interbreeding the heterozygous
Fanca+/ with p53+/ mice (C57BL/6: B6, CD45.2+; Jackson Laboratories) (Jacks et al., 1994). p53515C/515C Fanca/ mice were generated by interbreeding the Fanca+/ with p53515C/+ mice. All the
animals including the BoyJ (C57BL/6: B6, CD45.1+) mice were
maintained in the animal barrier facility at Cincinnati Children’s
Hospital Medical Center. All the animals used for the experiments
were 8–20 weeks old. All experimental procedures conducted in
this study were approved by the Institutional Animal Care and
Use Committee of Cincinnati Children’s Hospital Medical Center.

Bagby, G.C., Jr. (2003). Genetic basis of Fanconi anemia. Curr.
Opin. Hematol. 10, 68–76.

Statistical Analysis

Ceccaldi, R., Briot, D., Larghero, J., Vasquez, N., Dubois d’Enghien,
C., Chamousset, D., Noguera, M.E., Waisfisz, Q., Hermine, O.,
Pondarre, C., et al. (2011). Spontaneous abrogation of the G₂
DNA damage checkpoint has clinical benefits but promotes
leukemogenesis in Fanconi anemia patients. J. Clin. Invest 121,
184–194.

Student’s t test was performed using GraphPad Prism v6 (GraphPad
software). Comparison of more than two groups was analyzed by
one-way ANOVA test. p values <0.05 were considered statistically
significant. Results are presented as means ± SD. *p < 0.05;
**p < 0.01; ***p < 0.001.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures and can be found with this article online at https://
doi.org/10.1016/j.stemcr.2017.12.006.
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